We began investigating the shared effects of inhibiting mutationally activated oncogenes in both EGFR-mutant lung cancer cells and BRAF-mutant melanoma cells by analyzing changes in gene expression at 3, 6, and 9 days following addition of the EGFR inhibitor gefitinib or the BRAF inhibitor dabrafenib compared to untreated controls. This evidence concerns the gene EGFR and melanoma.